Tianjin CanSino Biotechnology Inc.

Tianjin CanSino Biotech Inc. is an emerging biotechnology company founded in 2009 with a strong focus on vaccine research, development, and commercialization. The company's mission is to address urgent unmet medical needs by creating and marketing cutting-edge, high-quality vaccines for China and other emerging markets at affordable prices. CanSino has made significant strides in this regard, having established bacterial and cell/viral culture pilot facilities in compliance with the current GMP standard. This enables the company to provide services to its clients and partners for the production of clinical trial material. In its most recent funding round on October 25, 2023, CanSino secured $2.00M in investment from a notable source, the Bill & Melinda Gates Foundation, indicating a strong vote of confidence in the company's vision and potential impact. With its headquarters in China, CanSino is strategically positioned to cater to the needs of the Asian market while also aiming to serve other emerging markets globally. Its focus on producing affordable vaccines aligns with the increasing demand for accessible healthcare solutions in these regions. Through its dedication to innovation in the field of biotechnology and commitment to addressing critical healthcare challenges, CanSino Biotech Inc. is poised to make significant contributions to the industry and society as a whole.